Evaluation of Vancomycin Treatment of Infections Due to Staphylococcus Aureus

Evaluation of Pharmacodynamic Target Attainment With Vancomycin Treatment of Infections Due to Staphylococcus Aureus

Objective: The objective of the study is to evaluate the ability of current vancomycin dosing strategies to attain the pharmacodynamic target of an area under the curve (AUC) to minimum inhibitory concentration (MIC) ratio greater than 400:1 for patients with a suspected or documented Staphylococcus aureus infection.

Primary Outcome: The primary outcome is the percentage of vancomycin dosing regimens that achieve AUC:MIC ratio > 400 on the first occurrence of vancomycin use in patients with a suspected or documented S. aureus infection at The Nebraska Medical Center.

Secondary Outcomes:

1. To assess the probability that vancomycin AUC:MIC ratios obtained from The Nebraska Medical Center patients exceed a therapeutic threshold using S. aureus MICs from isolates obtained from The Nebraska Medical Center.
2. Using MIC data from the TRUST Study database (large national surveillance database) and the vancomycin AUC data obtained from TNMC patients, perform a Monte Carlo analysis that will assess the probability of achieving a therapeutic vancomycin threshold with a large number of isolates.

Study Overview

• Status: Terminated
• Conditions: Staphylococcus Aureus

Detailed Description

Study Design: This is a prospective cohort study with a retrospective chart review component.

Inclusion and Exclusion Criteria: Inpatients of The Nebraska Medical Center will be included if they are 19 years of age or older, prescribed intravenous vancomycin therapy with a dosing interval of 24 hours or less, and therapy is continued for at least 3 doses or five half lives. Exclusion criteria consists of an estimated creatinine clearance less than 30 ml/min, concurrent use of dialysis, and pregnancy.

Interventions: For the prospective component eligible patients will be consented and enrolled. A vancomycin trough level will be determined as normal standard of care thirty minutes prior to the appropriate vancomycin dose, followed by a vancomycin peak level one hour after the end of the infusion. Serum concentration time data will then be used to calculate an AUC. The retrospective component of the study will involve a chart review of patients treated with vancomycin in which a serum trough and peak level was obtained and calculation of the AUC as described.

Evaluations: Serum concentration time data will be used to calculate an AUC for each patient enrolled in the study and from all charts reviewed that meet criteria. MIC data will be determined for Staphylococcus aureus isolates obtained from The Nebraska Medical Center. The two sets of data will then be used to calculate an AUC:MIC ratio. The AUC:MIC data will be compared to the goal ratio of greater than 400. Additionally, using the AUC data from our patients and the MICs derived from a large national surveillance data base, a Monte Carlo analysis will be completed to determine the probability of achieving therapeutic ratios.

• Study Type: Observational
• Enrollment (Actual): 250

Contacts and Locations

Study Locations

• United States
  • Nebraska
    • Omaha, Nebraska, United States, 68198
      • Unversity of Nebraska Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 19 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Adult patients with suspected or documentd staphylcoccus aureus infection and prescribed vancomycin

Description

Inclusion Criteria:

• 19 years of age or older
• Admitted to an inpatient care unit at The Nebraska Medical Center
• Prescribed intravenous vancomycin therapy with a dosing interval of 24 hours or less
• Vancomycin therapy that lasts for at least 3 doses or 5 half-lives as scheduled with no dosage changes

Exclusion Criteria:

• Estimated creatinine clearance (CrCl) less than 30 ml/min using the Cockroft-Gault equation (in patients over the age of 65 a SCr of 1.0 mg/dL will be assumed for all patients with a reported SCr less than 1.0 mg/dL). Ideal body weight will be used for the Cockroft-Gault equation unless the actual body weight is less than the ideal body weight.
• Patients requiring any form of dialysis
• Pregnancy

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of vancomycin dosing regimens achieving AUC:MIC ratio > 400	The primary outcome is the percentage of vancomycin dosing regimens that achieve AUC:MIC ratio > 400 on the first occurrence of vancomycin use in patients with a suspected or documented S. aureus infection at The Nebraska Medical Center.	12 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Therapeutic vancomycin threshold	Using MIC data from the TRUST Study database and the vancomycin AUC data obtained from TNMC patients, perform a Monte Carlo analysis that will assess the probability of achieving a therapeutic vancomycin threshold with a large number of isolates	12 months

Collaborators and Investigators

• Sponsor: University of Nebraska
• Investigators: Principal Investigator: Keith M Olsen, PharmD, University of Nebraska

Study record dates

Study Major Dates

• Study Start (Actual): April 1, 2009
• Primary Completion (Actual): February 3, 2011
• Study Completion (Actual): February 3, 2011

Study Registration Dates

• First Submitted: March 13, 2009
• First Submitted That Met QC Criteria: March 13, 2009
• First Posted (Estimated): March 17, 2009

Study Record Updates

• Last Update Posted (Actual): August 23, 2023
• Last Update Submitted That Met QC Criteria: August 19, 2023
• Last Verified: August 1, 2023

More Information

Terms related to this study

• Keywords: infection; vancomycin; staphylococcus aureus; pharmacodynammics
• Additional Relevant MeSH Terms: Bacterial Infections; Bacterial Infections and Mycoses; Gram-Positive Bacterial Infections; Infections; Staphylococcal Infections
• Other Study ID Numbers: 0002-09-FB